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Abstract Curcumin, the active constituent ofCurcuma longa
L. (family Zingiberaceae), has gained increasing interest be-
cause of its anti-cancer, anti-inflammatory, anti-diabetic, and
anti-rheumatic properties associated with good tolerability
and safety up to very high doses of 12 g. Nanoscaled micellar
formulations on the base of Tween 80 represent a promising
strategy to overcome its low oral bioavailability. We therefore
aimed to investigate the uptake and transepithelial transport of
native curcumin (CUR) vs. a nanoscaled micellar formulation
(Sol-CUR) in a Caco-2 cell model. Sol-CUR afforded a higher
flux than CUR (39.23 vs. 4.98 μg min−1 cm−2, respectively).
This resulted in a higher Papp value of 2.11 × 10
−6 cm/s for
Sol-CUR compared to a Papp value of 0.56 × 10
−6 cm/s for
CUR. Accordingly a nearly 9.5 fold higher amount of
curcumin was detected on the basolateral side at the end of
the transport experiments after 180 min with Sol-CUR com-
pared to CUR. The determined 3.8-fold improvement in the
permeability of curcumin is in agreement with an up to 185-
fold increase in the AUC of curcumin observed in humans
following the oral administration of the nanoscaled micellar
formulation compared to native curcumin. The present study
demonstrates that the enhanced oral bioavailability of micellar
curcumin formulations is likely a result of enhanced
absorption into and increased transport through small intesti-
nal epithelial cells.
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Introduction
Curcumin, the active constituent ofCurcuma longa L. (family
Zingiberaceae), has gained increasing interest because of its
anti-inflammatory, anti-diabetic, anti-rheumatic, anti-oxidant,
anti-cancer, wound healing, and hepatoprotective properties
associated with good tolerability and safety up to very high
doses of 12 g [1–4].
However, its low aqueous solubility, extensive intestinal
and hepatic metabolism, as well as rapid urinary excretion
limit its oral bioavailability to plasma concentrations in the
nanomolar range, even when ingested at single oral doses of
10–12 g [5, 6].
In order to overcome the low bioavailability of curcumin, a
number of different strategies have been pursued to enhance
its solubility, including the use of adjuvants to inhibit its me-
tabolism [7], the application of crystalline curcumin in mi-
cronized form [8] and the incorporation of curcumin into
phosphatidylcholine liposomes [9] or micelles [10, 11].
Nanoencapsulation of curcumin, using synthetic and natural-
based polymers has been mainly used for intravenous cancer
therapy [12]. Only two studies reported improved bioavail-
ability of PLGA-PEG encapsulated curcumin nanoparticles
and a liposomal nanoparticle formulation in rats following
oral administration [13, 14]. Recently, curcumin-loaded self-
assembled polymeric micelles were prepared using di-
tocopherol polyethylene glycol 2000 succinate (TPGS),
HS15 (octadecanoic acid, 12-hydroxy-polymer with alpha-
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hydro-omega-hydroxypoly (oxy-1,2-ethanediyl)) and
Pluronic F127 [15]. Another promising approach for the effi-
cient delivery of poorly soluble substances is the preparation
of nanoscaled micellar formulations based on Tween 80,
which enhance curcumin bioavailability up to 185-fold in
humans [10, 11]. We therefore investigated the transepithelial
transport and cellular accumulation of curcumin, demethoxy-
curcumin (DMC, curcumin II) and bis-demethoxycurcumin
(BDMC, curcumin III) in their native form compared to a
nanoscaled micellar formulation in a Caco-2 cell model.
Materials and Methods
Curcumin Formulations
Native curcumin powder composed of 82 % curcumin, 16 %
DMC and 2 % BMDC used for the transport studies and for
the preparation of the Tween 80 based micellar formulation
was purchased from Jupiter Lys (Cochin, Kerala State, India).
Sol-CUR consisting of 7% curcuminoid powder (equal to 6%
curcumin) and 93%Tween-80 (Kolb, Hedingen, Switzerland)
was produced by AQUANOVA AG (Darmstadt, Germany).
A dose of 98 mg total curcuminoids (80.36 mg curcumin,
15.68 mg DMC and 1.96 mg BDMC) was used for the trans-
port experiments with native and micellar curcumin.
The sample solution of Sol-CUR used for the transport
experiments was prepared by diluting 53 mg of Sol-CURwith
10 mL modified FaSSIF (fasted state simulated intestinal flu-
id) transport buffer. The sample solution of CURwas prepared
by diluting 32 mg native curcumin powder with 10 mL mod-
ified FaSSIF transport buffer and further diluting an aliquot of
1 mL from that solution with 9 mLmodified FaSSIF transport
buffer. Both sample solutions yielded a curcumin concentra-
tion of 320 μg/mL (869 μmol/L) corresponding to a dose of
80 mg curcumin taken together with a glass of 250 mL water.
Cell Culture Conditions
Differentiated Caco-2 cells (passages 24–36; American Type
Culture Collection (ATCC), Maryland, USA) were plated at a
density of 6.5 × 104 cells per cm2 on 12-well Transwell plates
(1.2 cm2 polycarbonate membrane, 0.4 μm pore size;
Corning, NY, USA) and grown in Dulbecco’s modified
Eagle’s medium (DMEM) containing 25 mM glucose supple-
mented with 10 % FCS (fetal calf serum), 1 % NEAA (non
essential amino acids) and 0.01 % gentamycin (all from
Biochrom AG, Berlin, Germany) in an atmosphere consisting
of 90 % relative humidity with 10 % CO2 at 37 °C.
Modified FaSSIF (fasted state simulated intestinal fluid),
containing 3 mM taurocholate sodium and 0.75 mM phospha-
tidylcholine in dihydrogenphosphate sodium buffer
(28.66 mM), was prepared by diluting appropriate amounts
of Phares SIF powder (Phares AG, Muttenz, Switzerland)
with HBSS transport medium, composed of Hanks balanced
salt solution (HBSS; Biochrom AG, Berlin, Germany) con-
t a in ing 20 mM HEPES (4- (2 -hydroxye thy l ) -1 -
piperazineethanesulfonic acid; Sigma-Aldrich, Steinheim,
Germany) buffered at a pH of 7.4.
Permeability Experiments
Permeation was investigated in apical-to-basolateral direction
(AB) at 37 °C (n = 6 each). During transport the plates were
agitated on a shaker at 120 rpm and kept at a constant temper-
ature of 37 °C. Prior to each experiment, the Caco-2 mono-
layers were washed with HBSS. The transepithelial electrical
resistance (TEER) was measured before and after the transport
experiments. FITC–Dextran (mean MW 4400 g/mol, Sigma-
Aldrich) was used to gauge the integrity of the monolayers and
propranolol hydrochloride (Fagron, Barsbüttel, Germany)
served as positive control for the functionality of every cell
passage (n = 6). The validity of the Caco-2 system in the present
study was ensured by TEER values greater 250 Ω cm2 and an
average Papp value for propranolol of 56.77 × 10
−6 cm/s [16].
To estimate the mass flux, the receiver fluid (1500 μL) was
withdrawn after 15, 30, 45, 60, 90, 120 and 180 min, and
replaced by an equal volume of fresh buffer solution, respec-
tively. The donor fluid (500 μL) was removed at the end of the
transport experiments to determine the remaining apical
curcuminoid concentrations. Furthermore each transwell filter
was vortexed in 0.5 mL methanol for 15 min at the end of the
incubation time. The resulting cell lysate was subjected to
HPLC analysis to determine the accumulated curcuminoids
in the Caco-2 cells. In addition, the initial curcuminoid con-
centrations (t0) were determined in the CUR and Sol-CUR
sample solution prior to the transport experiments.
Quantification of Curcumin
Sample preparation and analysis of curcuminoids were previ-
ously reported in detail [10, 11]. Briefly, one mL fluid was
acidified with 10 μL 6M hydrochloric acid and incubated with
100 μL beta-glucuronidase type H1 fromHelix pomatia (1 mg/
100 μL in 0.1M sodium acetate buffer, Sigma-Aldrich Chemie
GmbH, Schnelldorf, Germany) for 45 min at 37 °C. After trip-
licate extraction with 95 % ethyl acetate and 5 % methanol (v/
v), supernatants were evaporated to dryness and resuspended in
150 μL methanol, vortexed for 20 s, stored in the dark for
10 min, vortexed for 20 s and transferred to HPLC vials.
Twenty μL of each sample was injected into the HPLC system.
Curcuminoids were quantified on a Jasco HPLC system
(Jasco GmbH, Gross-Umstadt, Germany) with a fluorescence
detector (excitation wavelength 426 nm, emission wavelength
536 nm) and separated on a Reprosil-Pur C18-AQ column
(150 mm × 4 mm, 3 μm particle size; Dr. Maisch GmbH,
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Ammerbuch, Germany) maintained at 40 °C. The mobile
phase consisted of 52 % de-ionized water (adjusted to pH 3
with perchloric acid), 34 % acetonitrile and 14 % methanol.
Curcuminoids were quantified against external standard
curves (curcumin, purity ≥97.2 %, CAS # 458–37-7; DMC,
purity ≥98.3 %, CAS # 22,608–11-13; BDMC, purity
≥99.4 %, CAS # 24,949–16-; Chromadex, Irvine, USA).
Calculation of the Flux and Permeability Coefficient
The flux was calculated over the linear range of the perme-
ation curve for each well using the formula (dc/dt) × (1/A),
where dc/dt indicates the slope of the permeation and A the
surface area of the monolayer.
The permeability coefficient Papp (cm/s) was calculated as
follows: (dC/dt) × (Vr/AC0), where dc/dt is the flux rate (μg/
(mL × s)) through the monolayer, Vr is the volume of the re-
ceiver chamber (mL), A is the surface area of the cell monolayer,
and C0 is the initial concentration of the donor fluid (μg/mL).
Results and Discussion
The Caco-2 cell system, being recommended by the US Food
and Drug Administration (FDA), is an established and widely
accepted in vitro tool for predicting the intestinal absorption of
organic substances (Fig. 1) [17–19]. In the present study,
curcumin was dissolved in modified FASSIF to simulate the
gastrointestinal content at the site of absorption in the fasted
state. No additional solubility enhancing surfactants were used
asmodified FASSIF already contains taurocholate sodium and
lecithin as solubilizing enhancers.
At the end of the transport experiments, Sol-CUR afforded a
nearly 9.5 fold higher concentration of curcumin on the
basolateral side (transepithelial transport) compared to CUR,
while the amount of curcumin accumulated in the Caco-2 cells
was much lower with Sol-CUR than CUR (Fig. 2), suggesting
that the nanoscaled micellar formulation does not only increase
the cellular uptake, but also the basolateral secretion of curcumin.
The higher amount of Sol-CUR on the basolateral site re-
sults from a higher transport rate compared to CUR and a
higher flux of 39.23 μg min−1 cm−2 for Sol-CUR compared
to 4.98 μg min−1 cm−2 for CUR (Fig. 3). Papp values for Sol-
CUR and CUR were 2.11 × 10−6 cm/s and 0.56 × 10−6 cm/s,
respectively. Also, the permeability of Caco-2 cells for BDMC
and DMC was increased as demonstrated by the higher Papp
values obtained for BDMC and DMC in the nanoscaled mi-
cellar formulation compared to native curcumin (Table 1).
Compared to the Papp values for native curcumin of
0.05 × 10−6 cm/s and 0.07 × 10−6 cm/s reported in the
Fig. 1 Experimental setting of
the Caco-2 transport experiments
Fig. 2 Curcumin concentrations
(n = 6; mean ± SD) in the apical
and basolateral compartments and
in the cell pellets of Caco-2 cells
incubated for 180 min with
identical doses of native (CUR)
and nanoscaled micellar curcumin
(Sol-CUR)
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literature by Wang et al. and Dempe et al., respectively, the
Papp value determined in our study was higher [15, 20]. These
differences may be attributed to differences in the experimen-
tal conditions. Transport experiments in both studies were
performed with HBSS on the apical side, which is supple-
mented with glucose (25 mM) and buffered with 10 mM
HEPES at a pH of 7.4. Although frequently used in Caco-2
transport experiments, this buffer does not reflect the physio-
logical conditions in vivo, since the absence of bile salts may
limit the solubility of highly lipophilic substances and may
thus affect the outcome of the Caco-2 transport experiments
[21]. Moreover this buffer promotes adsorption and/or non-
specific binding of highly lipophilic substances to device sur-
faces, especially in the absence of sink conditions [22]. In
order to overcome these drawbacks, the Caco-2 model used
in this study was adapted to more closely mimic physiological
conditions. This implied the provision of sink conditions as
in vivo, i.e., a sufficiently diluted dissolution system in the
receiver compartment that does not impede the dissolution
of curcumin by approaching saturation. The addition of 4%
BSA provided the necessary driving force, similar to in vivo,
where the drug absorbed across the intestinal epithelium is
immediately carried away by the portal blood containing
about 4% albumin [21]. Further adaptation to in vivo condi-
tions was achieved by using modified FASSIF instead of pure
HBSS in the apical compartment. The taurocholate sodium
and lecithin included in modified FASSIF simulate the colloi-
dal mixture of bile salts and phosphatidylcholine in the intes-
tine, which are responsible for enhanced solubilisation effects
in vivo. Thus, the enhanced initial solubility of curcumin in the
apical compartment in combination with the provided sink
conditions, led to a higher Papp value for native curcumin than
that published before [15, 20]. A higher Papp value for native
curcumin of 2.9 × 10−6 cm/s was reported only in one study,
which may be explained by the much higher initial concentra-
tion of curcumin of 170 μmol/L used, a transition time of only
120 min and a pH of 6.5 in the apical compartment at which
curcumin is more stable [23].
The Papp value of 2.11 × 10
−6 cm/s for Sol-CUR observed
in the present study, indicating a 3.8-fold improvement in the
permeability of micellar curcumin over the native form, sug-
gests that the enhanced oral bioavailability of micellar
curcumin formulations reported in two human pharmacoki-
netic studies, resulting in an up to 185-fold increase in the
AUC compared to native curcumin [10, 11], is likely a result
of enhanced absorption into and increased transport through
small intestinal epithelial cells. The present study is the first to
provide insights into the processes underlying the observed
enhanced bioavailability of nanoscaled micellar curcumin for-
mulations in humans, underlining thus the potential of the
Caco-2 cell model to serve as an excellent predictive tool for
the oral absorption of not only native compounds, but also
more complex drug-excipient formulations.
Also curcumin-loaded self-assembled polymeric micelles
made from TPGS2 K, HS15, and Pluronic F127 facilitated a
3.5- fold increase in permeability compared to native
curcumin [15]. In fact, both TPGS2 K and Tween 80 are
non-ionic surfactants improving the bioavailability of poorly
soluble drugs bymicellar solubilisation [23]. However, Tween
80-based micellar formulations are characterized by a better
surfactant to curcumin ratio. While the curcumin-loaded self-
assembled polymeric micelles consisted of curcumin, TPGS2
K, HS15 and Pluronic F127 in a ratio of 1:10:10:2
(ca. 4% curcuminoids corresponding to 3% curcumin) [15],
the Tween 80 micellar formulation consisted of 7% curcumi-
noids (corresponding to 6% curcumin) and 93% Tween-80.
Fig. 3 Curcumin flux
(μg min−1 cm−2) of native (CUR)
and nanoscaled micellar
curcumin. Sol-CUR across Caco-
2 monolayers (n = 6;
mean ± S.D.)
Plant Foods Hum Nutr (2017) 72:48–53 51
Consequently a lower amount of surfactants is required in the
nanoscaled Tween 80 micellar formulation than in case of the
curcumin-loaded self-assembled polymeric micelles. This is
of special benefit as the overall amount of surfactants admin-
istered orally may thus be reduced.
At the same time the increase in bioavailability achieved
with the nanoscaled Tween 80 micellar formulation is much
higher than with the curcumin-loaded-self-assembled poly-
meric micelles. Thus, an up to 185-fold increase in the AUC
of curcumin was observed in humans with the nanoscaled
micellar formulation, whereas the curcumin-loaded-self-
assembled polymeric micelles achieved only a 2.87-fold in-
crease in the AUC of curcumin compared to the native com-
pound [10, 11, 15]. Moreover, Tween 80 is much cheaper than
TPGS, rendering it a cost-effective option to enhance the de-
livery of poorly soluble compounds to target tissues.
Conclusion
The present study provides insight into the processes under-
lying the observed 185-fold enhanced bioavailability of
nanoscaled micellar curcumin formulation in two previously
conducted human pharmakokinetic studies. The increase in
the apparent permeability coefficient observed for micellar
over native curcumin in the Caco-2 in vitro system results
from a higher transport rate and a higher flux for micellar
curcumin through the intestinal barrier. Also the amount of
curcumin accumulated in the Caco-2 cells was much lower
in case of nanoscaled micellar curcumin, suggesting that the
micellation of curcumin does not only increase the cellular
uptake but also the basolateral secretion of curcumin.
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